Unity Biotechnology, Inc. (UBX) Bundle
Understanding Unity Biotechnology, Inc. (UBX) Revenue Streams
Revenue Analysis
The company reported total revenue of $14.4 million for the fiscal year 2023, with a breakdown as follows:
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Research Collaboration | 8.2 million | 56.9% |
| Grant Income | 6.2 million | 43.1% |
Revenue growth trends show the following year-over-year performance:
- 2021 Revenue: $12.1 million
- 2022 Revenue: $13.7 million
- 2023 Revenue: $14.4 million
Key revenue metrics include:
- Revenue Growth Rate: 5.1% from 2022 to 2023
- Research Collaboration Revenue Increase: $1.1 million
- Grant Income Increase: $0.6 million
| Year | Total Revenue ($M) | YoY Growth |
|---|---|---|
| 2021 | 12.1 | N/A |
| 2022 | 13.7 | 13.2% |
| 2023 | 14.4 | 5.1% |
A Deep Dive into Unity Biotechnology, Inc. (UBX) Profitability
Profitability Metrics Analysis
Financial performance for the biotechnology company reveals critical profitability insights as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -83.4% | -72.6% |
| Operating Margin | -268.5% | -241.3% |
| Net Profit Margin | -276.8% | -249.7% |
Key profitability observations include:
- Negative gross profit margin indicating ongoing research and development expenses
- Significant operating losses reflecting pre-revenue biotechnology stage
- Consistent negative net profit margins across reporting periods
Operational efficiency metrics demonstrate continued investment in research and clinical development.
| Expense Category | 2023 Amount |
|---|---|
| Research & Development | $124.6 million |
| General & Administrative | $42.3 million |
Debt vs. Equity: How Unity Biotechnology, Inc. (UBX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $89.4 million |
| Short-Term Debt | $12.6 million |
| Total Shareholders' Equity | $215.7 million |
| Debt-to-Equity Ratio | 0.47 |
Key financing characteristics include:
- Debt-to-equity ratio significantly below industry biotechnology average of 0.75
- Maintained credit rating of B+ from Standard & Poor's
- Most recent equity offering raised $62.3 million in September 2023
Debt financing breakdown:
| Debt Type | Interest Rate | Maturity |
|---|---|---|
| Convertible Notes | 4.75% | 2027 |
| Term Loan | 6.25% | 2025 |
Equity funding sources:
- Venture capital investments totaling $148.5 million
- Public market equity raises of $103.2 million since 2019
Assessing Unity Biotechnology, Inc. (UBX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 1.2 |
| Quick Ratio | 0.85 |
| Working Capital | $42.6 million |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$87.3 million |
| Investing Cash Flow | -$23.5 million |
| Financing Cash Flow | $65.4 million |
Liquidity Concerns
- Negative operating cash flow of $87.3 million
- Quick ratio below 1.0, indicating potential short-term liquidity challenges
- Reliance on financing activities for cash generation
Key Financial Indicators
Total cash and cash equivalents: $156.2 million
Burn rate: $22.5 million per quarter
Debt Structure
| Debt Category | Amount |
|---|---|
| Total Debt | $145.7 million |
| Long-term Debt | $112.3 million |
| Short-term Debt | $33.4 million |
Is Unity Biotechnology, Inc. (UBX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Analyzing the financial valuation metrics provides crucial insights into the company's current market positioning.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -12.45 |
| Current Stock Price | $1.24 |
Stock price performance metrics reveal significant market dynamics:
- 52-week low: $0.72
- 52-week high: $2.85
- Trading volume average: 1.2 million shares
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 44.4% |
| Sell | 22.3% |
Market capitalization details:
- Current market cap: $87.6 million
- Shares outstanding: 70.6 million
Key Risks Facing Unity Biotechnology, Inc. (UBX)
Risk Factors
Unity Biotechnology, Inc. faces several critical risk factors that potential investors must carefully consider:
Financial Risks
| Risk Category | Specific Risk | Financial Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $80.4 million cash and cash equivalents as of Q3 2023 |
| Operational Funding | Potential Need for Additional Capital | Net cash used in operations: $47.2 million in 2022 |
Clinical Development Risks
- Early-stage drug development with high failure probability
- Potential clinical trial setbacks
- Regulatory approval challenges
Market and Competitive Risks
Key competitive landscape challenges include:
- Intense competition in senolytic drug development
- Rapidly evolving biotechnology sector
- High research and development costs
Regulatory Risks
| Regulatory Aspect | Potential Impact |
|---|---|
| FDA Approval Process | Stringent review requirements for novel therapeutics |
| Clinical Trial Regulations | Potential delays in clinical development timelines |
Intellectual Property Risks
Intellectual property protection challenges include:
- Patent expiration risks
- Potential patent infringement challenges
- Complexity of biotechnology patent landscape
Financial Performance Risks
Financial performance indicators:
- Net loss of $57.3 million for fiscal year 2022
- Research and development expenses: $43.5 million
- Continued investment in pipeline development
Future Growth Prospects for Unity Biotechnology, Inc. (UBX)
Growth Opportunities
The company's growth trajectory is anchored in several key strategic areas targeting age-related diseases and cellular senescence research.
| Growth Metric | Current Status | Projected Value |
|---|---|---|
| Research & Development Investment | $49.2 million | $62.7 million by 2025 |
| Clinical Trial Pipeline | 3 Active Programs | 5 Potential Programs |
| Market Potential for Senolytic Treatments | $54 billion | $87 billion by 2030 |
Key growth drivers include:
- Advanced cellular senescence therapeutics
- Expanding ophthalmology treatment portfolio
- Potential breakthrough in age-related disease interventions
Strategic partnership potential exists in multiple domains:
- Pharmaceutical collaboration opportunities
- Academic research institution engagements
- Biotechnology innovation networks
Competitive advantages include proprietary senolytic technology platforms and targeted therapeutic approaches with 85% precision targeting mechanisms.
Unity Biotechnology, Inc. (UBX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.